Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment

Figure 1 Viral responses and clinical courses in a 46-year-old man with chronic hepatitis (patient 1). The underline represents sequential evolution of lamivudine- or adeforvir- resistant genotypic mutations in HBV polymerase gene. LMV: Lamivudine; ADV: Adefovir; ETV: Entecavir; ALT: Alanine aminotransferase.

Figure 2 Viral responses and clinical courses in a 49-year-old man with compensated cirrhosis (patient 2). The underline represents sequential evolution of lamivudine- or adeforvir- resistant genotypic mutations in HBV polymerase gene. LMV: Lamivudine; ADV: Adefovir; ALT: Alanine aminotransferase.

Figure 3 Viral responses and clinical courses in a 50-year-old woman with decompensated cirrhosis (patient 3). The underline represents sequential evolution of lamivudine- or adeforvir- resistant genotypic mutations in HBV polymerase gene. LMV: Lamivudine; ADV: Adefovir; ALT: Alanine aminotransferase.

Figure 4 Viral responses and clinical courses in 50-year-old man with compensated cirrhosis (patient 4). The underline represents sequential evolution of lamivudine- or adeforvir- resistant genotypic mutations in HBV polymerase gene. LMV: Lamivudine; ADV: Adefovir; ALT: Alanine aminotransferase.